Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Guevara-Coto

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
BMC Genomics|January 7, 2015
Protein sector analysis for the clustering of disease-associated mutationsJose Guevara-Coto, Charles E Schwartz, Liangjiang Wang
Cells|February 15, 2022
Multistability in Macrophage Activation Pathways and Metabolic ImplicationsCarsten Geiß, Elvira Salas, Jose Guevara-Coto, et al.
Frontiers in Immunology|July 15, 2021
Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine LearningBruce K Patterson, Jose Guevara-Coto, Ram Yogendra, et al.
Frontiers in Medicine|February 27, 2023
Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)Bruce K Patterson, Ram Yogendra, Jose Guevara-Coto, et al.
Frontiers in Medicine|May 30, 2024
Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)Bruce K Patterson, Ram Yogendra, Jose Guevara-Coto, et al.
Scientific Reports|August 26, 2024
Long COVID diagnostic with differentiation from chronic lyme disease using machine learning and cytokine hubsBruce K Patterson, Jose Guevara-Coto, Javier Mora, et al.
Human Vaccines & Immunotherapeutics|May 13, 2025
Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individualsBruce K Patterson, Ram Yogendra, Edgar B Francisco, et al.
Frontiers in Immunology|January 27, 2022
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-InfectionBruce K Patterson, Edgar B Francisco, Ram Yogendra, et al.
Frontiers in Immunology|May 11, 2026
Correction: Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infectionBruce K Patterson, Edgar B Francisco, Ram Yogendra, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
BMC Genomics|January 7, 2015
Protein sector analysis for the clustering of disease-associated mutationsJose Guevara-Coto, Charles E Schwartz, Liangjiang Wang
Cells|February 15, 2022
Multistability in Macrophage Activation Pathways and Metabolic ImplicationsCarsten Geiß, Elvira Salas, Jose Guevara-Coto, et al.
Frontiers in Immunology|July 15, 2021
Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine LearningBruce K Patterson, Jose Guevara-Coto, Ram Yogendra, et al.
Frontiers in Medicine|February 27, 2023
Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)Bruce K Patterson, Ram Yogendra, Jose Guevara-Coto, et al.
Frontiers in Medicine|May 30, 2024
Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)Bruce K Patterson, Ram Yogendra, Jose Guevara-Coto, et al.
Scientific Reports|August 26, 2024
Long COVID diagnostic with differentiation from chronic lyme disease using machine learning and cytokine hubsBruce K Patterson, Jose Guevara-Coto, Javier Mora, et al.
Human Vaccines & Immunotherapeutics|May 13, 2025
Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individualsBruce K Patterson, Ram Yogendra, Edgar B Francisco, et al.
Frontiers in Immunology|January 27, 2022
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-InfectionBruce K Patterson, Edgar B Francisco, Ram Yogendra, et al.
Frontiers in Immunology|May 11, 2026
Correction: Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infectionBruce K Patterson, Edgar B Francisco, Ram Yogendra, et al.
Pageof 1